Galecto has been granted a patent for an a-D-galactopyranose compound (formula provided) for treating disorders related to galectin binding in mammals. The compound can be used in methods to address these disorders, particularly involving galectin-1 and ligand interactions in humans. GlobalData’s report on Galecto gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Galecto Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Galecto, NSAID cancer drugs was a key innovation area identified from patents. Galecto's grant share as of January 2024 was 37%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11827666B2) discloses a series of D-galactopyranose compounds with specific structural variations, aimed at targeting disorders related to the binding of galectin-1 to a ligand in mammals. The compounds described in the patent encompass various substitutions on the D-galactopyranose backbone, including different phenyl and pyridinyl groups, as well as specific halogen and alkyl substitutions. These compounds are intended for use in pharmaceutical compositions along with pharmaceutically acceptable additives.

Furthermore, the patent claims a method for treating a range of disorders associated with galectin-1 binding in mammals. These disorders include inflammation, fibrosis, cancer, autoimmune diseases, heart disease, metabolic disorders, and various other conditions related to abnormal scar formation, angiogenesis, and organ-specific diseases. The method involves administering a therapeutically effective amount of the disclosed compounds to mammals in need of treatment for the specified disorders. The compounds are proposed to have potential applications in addressing a wide array of medical conditions, from cancer and autoimmune diseases to metabolic disorders and lung diseases, highlighting the broad therapeutic scope of the patented compounds.

To know more about GlobalData’s detailed insights on Galecto, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies